Skip to content
Skip to content
Open navigation

Cancer Immunotherapy Update

Regular Price: $20.00
Online CE Expiration: 09/01/2023
1.5 Contact Hours
Presented by Ana

Nurses play a pivotal and strategic role in immunotherapy treatment. By understanding how the treatment process works and the possible adverse effects, nurses can help better educate patients. Nurses can also assist their patients in setting reasonable expectations and clarifying treatment goals. Learn more about immunotherapy in this article.

List Price:
$20.00
ANA Member Price:
$15.00

For bulk or invoice purchases, please contact customerservice@ana.org

Course Details

Cancer Immunotherapy Update

Overview

Because cancer treatment (surgery, radiation, and chemotherapy) frequently fails, researchers began asking why patients’ immune systems do not respond to cancer cells like they do to bacteria and viruses. Under normal conditions, T lymphocytes (T-cells) bind to a tumor cell via programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) receptors and then send signals that recruit antigen-presenting cells (APCs) that attach to the T-cells via the cytotoxic T lymphocyte antigen-4 (CT-LA-4) binding arm. Next, a series of cytokines (such as gamma interferon, interleukin 12 and B7) work to kill the T-cell and the tumor cell through apoptosis (cell death). Cancer tumor cells, however, block T-cells from binding to dendritic cells, allowing the cancer to escape detection by the patient’s immune system.

The U.S. Food and Drug Administration (FDA) has approved several immunotherapy agents to treat cancer. They help the immune system recognize tumor cells, prevent immune system tolerance of tumor cells, and manipulate translational proteins in the tumor microenvironment. However, these drugs come with accompanying toxicities (immune-related adverse effects). This article focuses on two recently approved treatments—immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy—their immune-related adverse effects, and treatment options. By understanding how these treatments work and their possible adverse effects, nurses can better educate patients and intervene quickly when necessary.

Key Learning Outcomes

  1. Describe how immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy work.
  2. Discuss adverse effects related to immune checkpoint inhibitors.
  3. Discuss adverse effects related to CAR T-cell therapy.

Presented by:

Victoria L. Anderson, MSN, CRNP, FAANP is a senior nurse practitioner in the Laboratory of Clinical Immunology and Microbiology, Immunopathogenesis Section at the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH) in Bethesda, Maryland.

Leslie Smith, MSN, RN, AOCNS, APRN-CNS is a clinical nurse specialist in oncology, blood and marrow transplant at the NIH Clinical Center Nursing Department in Bethesda, Maryland.

Location Details

Accreditation Statements

The American Nurses Association is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

ANA is approved by the California Board of Registered Nursing, Provider Number CEP17219.

You might also like

You are now leaving the American Nurses Foundation

The American Nurses Foundation is a separate charitable organization under Section 501(c)(3) of the Internal Revenue Code. The Foundation does not engage in political campaign activities or communications.

The Foundation expressly disclaims any political views or communications published on or accessible from this website.

Continue Cancel

Item(s) added to cart

Go to cart Continue Shopping